Over 80% of glioblastomas have an acquired alteration in the RTK/PI3K/AKT pathway with about 40% of tumors having some alteration in EGFR [3], [5] suggesting that scarcity of a prevalent alteration is not the problem with targeted therapy in most GBMs. The gene discussed is AKT1; the disease is glioblastoma.